Xerostomia Due to Hyposecretion of Salivary Gland
8
0
0
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (8)
Hyaluronic Acid in the Treatment of Hyposalivation
Repeated Mesenchymal Stem Cell Therapy for Radiation-Induced Hyposalivation and Xerostomia in Head and Neck Cancer Survivors
This Present Study Can be Used by Clinicians Who Treat Psychiatric Patients: Dentists Might Expect Xerogenic Side Effects of Specific Psychiatric Drugs Which Can Affect Dental Treatment, and the Results Can Help Psychiatrist to Choose the Less Xerogenic Psychiatric Medication
Chamomile Effect on Xerostomia Associated With End-stage Renal Disease in Elderly
Efficacy of a Dietary Supplement (Aqualief®) in Xerostomic Patients
Finger-prick Autologous Blood (FAB) for Use in Dry Mouth
The Artificial Saliva Spray Reduces Xerostomia in Diabetes Type II
Salivary Markers in Patients With Xerostomia